Mahmoud A Ghannoum

List of Publications by Citations

240 papers	14,107 citations	58 h-index	113 g-index
255 ext. papers	16,115 ext. citations	5.5 avg, IF	6.63 L-index

#	Paper	IF	Citations
240	Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. *Journal of Bacteriology*, **2001**, 183, 5385-94	3.5	1157
239	Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. *Clinical Microbiology Reviews*, **1999**, 12, 501-17	34	1113
238	Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathogens*, **2010**, 6, e1000713	7.6	659
237	Potential role of phospholipases in virulence and fungal pathogenesis. *Clinical Microbiology Reviews* , **2000**, 13, 122-43, table of contents	34	508
236	Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. *Infection and Immunity*, **2003**, 71, 4333-40	3.7	394
235	International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. *Clinical Infectious Diseases*, **1997**, 25, 43-59	11.6	362
234	Antifungal susceptibility testing: practical aspects and current challenges. *Clinical Microbiology Reviews*, **2001**, 14, 643-58, table of contents	34	326
233	Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. *Molecular Microbiology*, **2001**, 39, 166-75	4.1	286
232	Combination treatment of invasive fungal infections. *Clinical Microbiology Reviews*, **2005**, 18, 163-94	34	230
231	The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	222
230	Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. *PLoS Pathogens*, **2014**, 10, e1003996	7.6	207
229	Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. *Journal of Infectious Diseases*, **2003**, 188, 305-19	7	207
228	Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 82-6	5.9	206
227	The Gut Microbiome as a Major Regulator of the Gut-Skin Axis. *Frontiers in Microbiology*, **2018**, 9, 1459	5.7	181
226	In vitro growth and analysis of Candida biofilms. *Nature Protocols*, **2008**, 3, 1909-24	18.8	172
225	Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. *Journal of the American Academy of Dermatology*, **2004**, 50, 748-52	4.5	168
224	Mechanism of fluconazole resistance in Candida krusei. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 2645-9	5.9	167

223	Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1727-32	5.9	165
222	Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. *Journal of Clinical Microbiology*, **2004**, 42, 3475-82	9.7	163
221	Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. *Journal of Biological Chemistry*, **1998**, 273, 26078-86	5.4	163
220	Microbial contamination of contact lenses, lens care solutions, and their accessories: a literature review. *Eye and Contact Lens*, **2010**, 36, 116-29	3.2	156
219	Fusarium and Candida albicans biofilms on soft contact lenses: model development, influence of lens type, and susceptibility to lens care solutions. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 171-82	5.9	156
218	Resistance of Candida to azoles and echinocandins worldwide. *Clinical Microbiology and Infection*, **2019**, 25, 792-798	9.5	151
217	Onychomycosis: diagnosis and definition of cure. *Journal of the American Academy of Dermatology*, **2007**, 56, 939-44	4.5	139
216	RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. *Microbiology (United Kingdom)*, **2004**, 150, 267-275	2.9	136
215	Distinct roles for Dectin-1 and TLR4 in the pathogenesis of Aspergillus fumigatus keratitis. *PLoS Pathogens*, **2010**, 6, e1000976	7.6	134
214	The RodA hydrophobin on Aspergillus fumigatus spores masks dectin-1- and dectin-2-dependent responses and enhances fungal survival in vivo. *Journal of Immunology*, **2013**, 191, 2581-8	5.3	125
213	Increased resistance of contact lens-related bacterial biofilms to antimicrobial activity of soft contact lens care solutions. *Cornea*, **2009**, 28, 918-26	3.1	124
212	Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. *Clinical Infectious Diseases*, **1996**, 22, 322-8	11.6	123
211	Alcohol dehydrogenase restricts the ability of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism. *Infection and Immunity*, **2006**, 74, 3804-16	3.7	114
210	Candida parapsilosis characterization in an outbreak setting. *Emerging Infectious Diseases*, **2004**, 10, 1074-81	11.1	114
209	Temporal analysis of Candida albicans gene expression during biofilm development. *Microbiology (United Kingdom)*, **2007**, 153, 2373-2385	2.9	110
208	Candida biofilm: a well-designed protected environment. *Medical Mycology*, **2005**, 43, 191-208	3.9	109
207	Modification of surface properties of biomaterials influences the ability of Candida albicans to form biofilms. *Applied and Environmental Microbiology*, **2005**, 71, 8795-801	4.8	108
206	Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. *Diagnostic Microbiology and Infectious Disease*, **2011**, 70, 330-43	2.9	106

205	Mycobiota in gastrointestinal diseases. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 77-87	24.2	105
204	Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. *Infection and Immunity*, **2007**, 75, 2612-20	3.7	105
203	Effectiveness of Disinfectants Against Candida auris and Other Candida Species. *Infection Control and Hospital Epidemiology*, **2017**, 38, 1240-1243	2	104
202	Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species. *Infection Control and Hospital Epidemiology*, **2017**, 38, 1107-1109	2	101
201	Candida biofilms: antifungal resistance and emerging therapeutic options. *Current Opinion in Investigational Drugs*, **2004**, 5, 186-97		100
200	The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn's Disease-Like Ileitis. *Inflammatory Bowel Diseases*, **2018**, 24, 1005-1020	4.5	97
199	Antifungal hydrogels. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12994-8	11.5	90
198	Voriconazole -- better chances for patients with invasive mycoses. *European Journal of Medical Research*, **2002**, 7, 242-56	4.8	90
197	and Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	87
196	Novel FKS mutations associated with echinocandin resistance in Candida species. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2225-7	5.9	83
195	Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation. *Microbiology (United Kingdom)*, **2011**, 157, 3232-3242	2.9	81
194	Cloning and characterization of a gene (LIP1) which encodes a lipase from the pathogenic yeast Candida albicans. *Microbiology (United Kingdom)*, **1997**, 143 (Pt 2), 331-340	2.9	81
193	Fungal nail infections (onychomycosis): a never-ending story?. *PLoS Pathogens*, **2014**, 10, e1004105	7.6	77
192	Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14□demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1162-9	5.9	74
191	Novel antiseptic urinary catheters for prevention of urinary tract infections: correlation of in vivo and in vitro test results. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 5145-9	5.9	72
190	Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. *International Journal of Medical Microbiology*, **2010**, 300, 265-70	3.7	70
189	Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. *International Journal of Antimicrobial Agents*, **2007**, 30, 551-4	14.3	70
188	MyD88 regulation of Fusarium keratitis is dependent on TLR4 and IL-1R1 but not TLR2. *Journal of Immunology*, **2008**, 181, 593-600	5.3	67

187	Mechanisms of fungal resistance: an overview. *Drugs*, **2002**, 62, 1025-40	12.1	67
186	New investigational antifungal agents for treating invasive fungal infections. *Expert Opinion on Investigational Drugs*, **2000**, 9, 1797-813	5.9	67
185	Characterization of fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis **2012**, 53, 4450-7		60
184	Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo. *Microbiology (United Kingdom)*, **2001**, 147, 2585-2597	2.9	59
183	Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. *International Journal of Antimicrobial Agents*, **2009**, 33, 149-53	14.3	58
182	Methodologies for and evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. *Microbial Cell*, **2018**, 5, 300-326	3.9	57
181	A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. *Journal of the American Academy of Dermatology*, **2005**, 53, 798-809	4.5	57
180	Azole Resistance in Dermatophytes: Prevalence and Mechanism of Action. *Journal of the American Podiatric Medical Association*, **2016**, 106, 79-86	1	55
179	Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method. *Journal of the American Academy of Dermatology*, **1999**, 40, S9-13	4.5	55
178	A murine model of contact lens-associated fusarium keratitis **2010**, 51, 1511-6		54
177	Bacteriome and mycobiome associations in oral tongue cancer. *Oncotarget*, **2017**, 8, 97273-97289	3.3	50
176	Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2085-2088	5.1	50
175	The mycobiome: Role in health and disease, and as a potential probiotic target in gastrointestinal disease. *Digestive and Liver Disease*, **2017**, 49, 1171-1176	3.3	49
174	SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	47
173	Photodynamic therapy with Pc 4 induces apoptosis of Candida albicans. *Photochemistry and Photobiology*, **2011**, 87, 904-9	3.6	47
172	Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. *Clinical Microbiology and Infection*, **2009**, 15, 274-9	9.5	47
171	Characterization of bacterial communities in venous insufficiency wounds by use of conventional culture and molecular diagnostic methods. *Journal of Clinical Microbiology*, **2011**, 49, 3812-9	9.7	47
170	Cutaneous hypersensitivity to Candida albicans in idiopathic vulvodynia. *Contact Dermatitis*, **2005**, 53, 214-8	2.7	47

169	Central venous catheter-associated Nocardia bacteremia in cancer patients. *Emerging Infectious Diseases*, **2011**, 17, 1651-8	10.2	46
168	Fungal biofilms and antimycotics. *Current Drug Targets*, **2005**, 6, 887-94	3	46
167	Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. *Mycoses*, **2009**, 52, 35-43	5.2	45
166	Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. *Haematologica*, **2008**, 93, 639-40	6.6	45
165	Novel role of a family of major facilitator transporters in biofilm development and virulence of Candida albicans. *Biochemical Journal*, **2014**, 460, 223-35	3.8	44
164	The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial-coated endotracheal tubes. *Biomaterials*, **2011**, 32, 2689-94	15.6	44
163	Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: toward novel diagnostic targets. *OMICS A Journal of Integrative Biology*, **2013**, 17, 5-15	3.8	42
162	Parenteral lipid emulsion induces germination of Candida albicans and increases biofilm formation on medical catheter surfaces. *Journal of Infectious Diseases*, **2009**, 200, 473-80	7	42
161	Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations. *Journal of Clinical Microbiology*, **2011**, 49, 1716-20	9.7	40
160	Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. *Journal of Antimicrobial Chemotherapy*, **2003**, 51, 1427-9	5.1	40
159	Relative Resistance of the Emerging Fungal Pathogen Candida auris and Other Candida Species to Killing by Ultraviolet Light. *Infection Control and Hospital Epidemiology*, **2018**, 39, 94-96	2	40
158	Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard. *Journal of Clinical Microbiology*, **2017**, 55, 1262-1268	9.7	39
157	VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1992-7	5.9	39
156	Iron deprivation induces EFG1-mediated hyphal development in Candida albicans without affecting biofilm formation. *FEMS Yeast Research*, **2008**, 8, 744-55	3.1	37
155	Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. *Vaccine Journal*, **1999**, 6, 921-3		37
154	A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1671-9	5.9	36
153	Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 4175-7	5.9	35
152	Single-step PCR using (GACA)4 primer: utility for rapid identification of dermatophyte species and strains. *Journal of Clinical Microbiology*, **2008**, 46, 2641-5	9.7	35

151	In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV-infected patients. *International Journal of Antimicrobial Agents*, **2008**, 31, 272-6	14.3	34
150	Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. *International Journal of Dermatology*, **2003**, 42 Suppl 1, 11-7	1.7	34
149	Inhibition of monocytic interleukin-12 production by Candida albicans via selective activation of ERK mitogen-activated protein kinase. *Infection and Immunity*, **2004**, 72, 2513-20	3.7	34
148	Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. *AIDS Research and Human Retroviruses*, **1999**, 15, 1619-23	1.6	34
147	Interlaboratory study of quality control isolates for a broth microdilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals. *Journal of Clinical Microbiology*, **2006**, 44, 4353-6	9.7	33
146	Endothelial cell injury caused by Candida albicans is dependent on iron. *Infection and Immunity*, **1998**, 66, 191-6	3.7	33
145	The Role of Echinocandins in Candida Biofilm-Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems. *Clinical Infectious Diseases*, **2015**, 61 Suppl 6, S618-21	11.6	32
144	Candida biofilms associated with CVC and medical devices. *Mycoses*, **2012**, 55, 46-57	5.2	31
143	Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 438-40	5.9	31
142	Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates. *Medical Mycology*, **2004**, 42, 525-9	3.9	31
141	Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status. *Aids*, **2018**, 32, 1279-1287	3.5	29
140	In vitro antifungal activity of naftifine hydrochloride against dermatophytes. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4369-72	5.9	29
139	Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 1543-8	5.9	29
138	Hyphae and yeasts of Candida albicans differentially regulate interleukin-12 production by human blood monocytes: inhibitory role of C. albicans germination. *Infection and Immunity*, **2001**, 69, 4695-7	3.7	29
137	Candida albicans and Candida krusei differentially induce human blood mononuclear cell interleukin-12 and gamma interferon production. *Infection and Immunity*, **2000**, 68, 2464-9	3.7	28
136	Effects of a Novel Probiotic Combination on Pathogenic Bacterial-Fungal Polymicrobial Biofilms. *MBio*, **2019**, 10,	7.8	27
135	Examining the importance of laboratory and diagnostic testing when treating and diagnosing onychomycosis. *International Journal of Dermatology*, **2018**, 57, 131-138	1.7	27
134	Novel quorum-quenching agents promote methicillin-resistant Staphylococcus aureus (MRSA) wound healing and sensitize MRSA to β-lactam antibiotics. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1512-8	5.9	27

133	Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. *Medical Mycology*, **2010**, 48, 491-7	3.9	27
132	Cutaneous hypersensitivity to Malassezia sympodialis and dust mite in adult atopic dermatitis with a textile pattern. *Contact Dermatitis*, **2006**, 54, 92-9	2.7	27
131	Potentiation of azole antifungals by 2-adamantanamine. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 3585-92	5.9	26
130	Development of a 96-well catheter-based microdilution method to test antifungal susceptibility of Candida biofilms. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 149-53	5.1	26
129	Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial. *British Journal of Dermatology*, **2008**, 159, 711-3	4	26
128	Cloning and characterization of CAD1/AAF1, a gene from Candida albicans that induces adherence to endothelial cells after expression in Saccharomyces cerevisiae. *Infection and Immunity*, **1998**, 66, 2078-84	3.7	25
127	Rhodococcus bacteremia in cancer patients is mostly catheter related and associated with biofilm formation. *PLoS ONE*, **2012**, 7, e32945	3.7	25
126	Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. *PLoS ONE*, **2018**, 13, e0200285	3.7	24
125	Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1500-2	5.9	24
124	New developments in chemotherapy for non-invasive fungal infections. *Expert Opinion on Investigational Drugs*, **2001**, 10, 1501-11	5.9	24
123	Molecular analysis of dermatophytes suggests spread of infection among household members. *Cutis*, **2013**, 91, 237-45	0.4	24
122	Ability of hydroxypropyl chitosan nail lacquer to protect against dermatophyte nail infection. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1844-8	5.9	23
121	Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis. *Journal of Antimicrobial Chemotherapy*, **2007**, 59, 556-9	5.1	23
120	A second look at efficacy criteria for onychomycosis: clinical and mycological cure. *British Journal of Dermatology*, **2014**, 170, 182-7	4	22
119	Shear stress modulates the thickness and architecture of Candida albicans biofilms in a phase-dependent manner. *Mycoses*, **2009**, 52, 440-6	5.2	22
118	Optimization of an infected shoe model for the evaluation of an ultraviolet shoe sanitizer device. *Journal of the American Podiatric Medical Association*, **2012**, 102, 309-13	1	22
117	Efficacy of care solutions against contact lens-associated Fusarium biofilms. *Optometry and Vision Science*, **2012**, 89, 382-91	2.1	22
116	The role of nondermatophyte molds in onychomycosis: diagnosis and treatment. *Dermatologic Therapy*, **2002**, 15, 89-98	2.2	22

115	Biofilm Antimicrobial Resistance **2004**, 250-268		22
114	Cooperative Evolutionary Strategy between the Bacteriome and Mycobiome. *MBio*, **2016**, 7,	7.8	22
113	Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1511-1519	4.7	21
112	Antifungal Resistance: Specific Focus on Multidrug Resistance in and Secondary Azole Resistance in. *Journal of Fungi (Basel, Switzerland)*, **2018**, 4,	5.6	21
111	Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis. *Expert Opinion on Investigational Drugs*, **2012**, 21, 1549-62	5.9	20
110	Evaluation of the morphological effects of TDT 067 (terbinafine in Transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 2530-4	5.9	20
109	Extracellular phospholipases as universal virulence factor in pathogenic fungi. *Medical Mycology Journal*, **1998**, 39, 55-9		20
108	Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma. *BBA Clinical*, **2017**, 7, 8-15		19
107	Disruption of sphingolipid biosynthetic gene IPT1 reduces Candida albicans adhesion and prevents activation of human gingival epithelial cell innate immune defense. *Medical Mycology*, **2011**, 49, 458-66	3.9	19
106	Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. *Journal of the American Academy of Dermatology*, **2002**, 46, 371-5	4.5	19
105	Effect of growth of Candida spp. in the presence of various glucocorticoids on the adherence to human buccal epithelial cells. *Mycopathologia*, **1987**, 98, 171-8	2.9	19
104	Small-molecule AgrA inhibitors F12 and F19 act as antivirulence agents against Gram-positive pathogens. *Scientific Reports*, **2018**, 8, 14578	4.9	19
103	The mycobiome in HIV. *Current Opinion in HIV and AIDS*, **2018**, 13, 69-72	4.2	17
102	Effects of voriconazole on Candida glabrata in vitro. *Journal of Antimicrobial Chemotherapy*, **1999**, 44, 109-12	5.1	17
101	Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an Guinea Pig Cutaneous Infection Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	17
100	Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes. *Journal of Clinical Microbiology*, **2008**, 46, 3668-71	9.7	16
99	High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group. *PLoS ONE*, **2015**, 10, e0131001	3.7	16
98	Polymeric Nanofiber/Antifungal Formulations Using a Novel Co-extrusion Approach. *AAPS PharmSciTech*, **2017**, 18, 1917-1924	3.9	15

97	Candida albicans RHO1 is required for cell viability in vitro and in vivo. *FEMS Yeast Research*, **2002**, 2, 103-11	3.1	15
96	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	15
95	CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	15
94	Silicon phthalocyanine 4 phototoxicity in Trichophyton rubrum. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3029-34	5.9	14
93	Decreased Fluconazole Susceptibility of a Relapse Cryptococcus neoformans Isolate After Fluconazole Treatment. *Infectious Diseases in Clinical Practice*, **1995**, 4, 318-319	0.2	14
92	A Novel Actin Binding Drug with Efficacy. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	14
91	The Mycobiome: Impact on Health and Disease States. *Microbiology Spectrum*, **2017**, 5,	8.9	13
90	Fungal Translocation Is Associated with Immune Activation and Systemic Inflammation in Treated HIV. *AIDS Research and Human Retroviruses*, **2019**, 35, 461-472	1.6	13
89	In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5154-8	5.9	13
88	Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status. *Aids*, **2017**, 31, 2077-2084	3.5	13
87	A rabbit model for evaluation of catheter-associated fungal biofilms. *Virulence*, **2011**, 2, 466-74	4.7	13
86	Candida: a causative agent of an emerging infection. *Journal of Investigative Dermatology Symposium Proceedings*, **2001**, 6, 188-96	1.1	13
85	Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. *Journal of the National Cancer Institute*, **2002**, 94, 718-32	9.7	13
84	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Infections. *Antibiotics*, **2020**, 9,	4.9	13
83	Identification of gentian violet concentration that does not stain oral mucosa, possesses anti-candidal activity and is well tolerated. *European Journal of Clinical Microbiology and Infectious Diseases*, **2011**, 30, 629-33	5.3	12
82	Antimicrobial activity of B-Lock against bacterial and Candida spp. causing catheter-related bloodstream infections. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 4430-1	5.9	12
81	A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. *Clinical Infectious Diseases*, **2021**, 73, e1518-e1524	11.6	12
80	Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis. *Journal of the American Podiatric Medical Association*, **2018**, 108, 12-19	1	12

79	Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants. *Aids*, **2017**, 31, 81-88	3.5	11
78	The natural diyne-furan fatty acid EV-086 is an inhibitor of fungal delta-9 fatty acid desaturation with efficacy in a model of skin dermatophytosis. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 455-68	5.9	11
77	Recombinant human granulocyte macrophage-colony stimulating factor expressed in yeast (sargramostim): A potential ally to combat serious infections. *Clinical Immunology*, **2020**, 210, 108292	9	11
76	Diversity of Ocular Surface Bacterial Microbiome Adherent to Worn Contact Lenses and Bacterial Communities Associated With Care Solution Use. *Eye and Contact Lens*, **2019**, 45, 331-339	3.2	11
75	Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes. *Mycoses* , **2010**, 53, 311-3	5.2	10
74	Gentian violet exhibits activity against biofilms formed by oral Candida isolates obtained from HIV-infected patients. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3043-5	5.9	10
73	Voriconazole and Caspofungin Cidality Against Non-Albicans Candida Species. *Infectious Diseases in Clinical Practice*, **2007**, 15, 250-253	0.2	10
72	Antifungal susceptibility testing of yeasts: uses and limitations. *Drug Resistance Updates*, **2000**, 3, 14-19	23.2	10
71	Animal models to investigate fungal biofilm formation. *Methods in Molecular Biology*, **2014**, 1147, 141-57	1.4	10
70	The Fungal Biome of the Oral Cavity. *Methods in Molecular Biology*, **2016**, 1356, 107-35	1.4	10
69	Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against. *Frontiers in Cellular and Infection Microbiology*, **2021**, 11, 642358	5.9	10
68	Influence of gut microbiome on multiple myeloma: friend or foe? **2020**, 8,		9
67	Repeated exposure of Candida spp. to miconazole demonstrates no development of resistance. *Mycoses*, **2011**, 54, e175-7	5.2	9
66	Anidulafungin. *Infectious Diseases in Clinical Practice*, **2005**, 13, 165-178	0.2	9
65	Emerging Issues in Antifungal Resistance. *Infectious Disease Clinics of North America*, **2020**, 34, 921-943	6.5	9
64	Antimicrobial Activity of Silver Containing Crosslinked Poly(Acrylic Acid) Fibers. *Micromachines*, **2019**, 10,	3.3	9
63	The monoclonal antibody Ca37, developed against Candida albicans alcohol dehydrogenase, inhibits the yeast in vitro and in vivo. *Scientific Reports*, **2020**, 10, 9206	4.9	7
62	Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay. *Dermatology and Therapy*, **2016**, 6, 69-75	4	7

61	Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 3231-3	5.9	7
60	Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata. *Mycopathologia*, **1986**, 95, 175-81	2.9	7
59	Quorum-sensing dysbiotic shifts in the HIV-infected oral metabiome. *PLoS ONE*, **2015**, 10, e0123880	3.7	7
58	Admission to the Intensive Care Unit is Associated With Changes in the Oral Mycobiome. *Journal of Intensive Care Medicine*, **2017**, 32, 278-282	3.3	6
57	Efficacy of NVC-422 in the treatment of dermatophytosis caused by Trichophyton mentagrophytes using a guinea pig model. *International Journal of Dermatology*, **2013**, 52, 567-71	1.7	6
56	Fungal Biofilms in the Clinical Lab Setting. *Current Fungal Infection Reports*, **2010**, 4, 137-144	1.4	6
55	A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails. *Mycoses*, **2019**, 62, 494-501	5.2	5
54	Treatment-resistant dermatophytosis: A representative case highlighting an emerging public health threat. *JAAD Case Reports*, **2020**, 6, 1153-1155	1.4	5
53	Evaluation of the Efficacy of ME1111 in the Topical Treatment of Dermatophytosis in a Guinea Pig Model. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2343-5	5.9	5
52	The Human Mycobiome and its Impact on Health and Disease. *Current Fungal Infection Reports*, **2013**, 7, 345-350	1.4	5
51	Susceptibility testing of dermatophytes. *Current Fungal Infection Reports*, **2009**, 3, 142-146	1.4	5
50	Clinical Effects of Gamma-Radiation-Resistant Aspergillus sydowii on Germ-Free Mice Immunologically Prone to Inflammatory Bowel Disease. *Journal of Pathogens*, **2016**, 2016, 5748745	1.9	5
49	Symbiosis and Dysbiosis of the Human Mycobiome. *Frontiers in Microbiology*, **2021**, 12, 636131	5.7	5
48	Evaluation of the Ability of a Novel Miconazole Formulation To Penetrate Nail by Using Three Nail Models. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	4
47	Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1759-66	5.9	4
46	Updates on Therapeutic Strategies Against Candida (and Aspergillus) Biofilm Related Infections. *Advances in Experimental Medicine and Biology*, **2016**, 931, 95-103	3.6	4
45	Aspergillus Biofilm In Vitro and In Vivo **2015**, 149-161		4
44	N-acetylcysteine lock solution prevents catheter-associated bacteremia in rabbits. *International Journal of Artificial Organs*, **2012**, 35, 893-7	1.9	4

43	Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111. *Journal of Clinical Microbiology*, **2016**, 54, 662-5	9.7	3
42	Candida albicans Biofilm Development and Its Genetic Control **2015**, 99-114		3
41	Fungal Biofilms **2004**, 30-42		3
40	Intestinal Stem Cell Niche Defects Result in Impaired 3D Organoid Formation in Mouse Models of Crohn's Disease-like Ileitis. *Stem Cell Reports*, **2020**, 15, 389-407	8	3
39	The Role of Dectin-1 Signaling in Altering Tumor Immune Microenvironment in the Context of Aging. *Frontiers in Oncology*, **2021**, 11, 669066	5.3	3
38	and Antifungal Activity of AmBisome Compared to Conventional Amphotericin B and Fluconazole against Candida auris. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	3
37	A Second-Generation Fungerp Analog, SCY-247, Shows Potent Activity against Candida auris and Other Clinically Relevant Fungal Isolates. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	3
36	Effect of an Emollient on the Mycobiome of Atopic Dermatitis Patients. *Journal of Drugs in Dermatology*, **2018**, 17, 1039-1048	2.2	3
35	Fungal Biofilms:In Vivo Models for Discovery of Anti-Biofilm Drugs **2015**, 33-49		2
34	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. *Clinical Infectious Diseases*, **2006**, 43, 1031-9	11.6	2
33	Yeast susceptibility testing: reference methods and commercial test systems. *Clinical Microbiology Newsletter*, **2001**, 23, 131-135	1.1	2
32	Fungal Biofilms: Agents of Disease and Drug Resistance177-185		2
31	A Novel Transdermal Application for Clearing Skin Colonization by. *Antimicrobial Agents and Chemotherapy*, **2021**,	5.9	2
30	Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: Improved understanding and new strategic approach with sargramostim. *Clinical Immunology*, **2021**, 228, 108731	9	2
29	Microbiome: Its Impact Is Being Revealed!. *Current Clinical Microbiology Reports*, **2017**, 4, 78-87	3.1	1
28	Oral Cytokine Levels Are More Linked to Levels of Plasma and Oral HIV-1 RNA Than to CD4 T-Cell Counts in People With HIV. *Open Forum Infectious Diseases*, **2020**, 7, ofaa047	1	1
27	The Mycobiome: Impact on Health and Disease States **2017**, 845-854		1
26	GM-CSF: Orchestrating the Pulmonary Response to Infection.. *Frontiers in Pharmacology*, **2021**, 12, 735443	5.6	1

25	Candida Biofilms: Development, Architecture, and Resistance115-134		1
24	Indole-3-acetic acid synthesized through the indole-3-pyruvate pathway promotes Candida tropicalis biofilm formation. *PLoS ONE*, **2020**, 15, e0244246	3.7	1
23	The Microbiome: More than Bacteria. *Microbe Magazine*, **2010**, 5, 459-459		1
22	Do Antifungals and Local Anesthetic Affect the Efficacy of Antibiotic Dipping Solution?. *Journal of Sexual Medicine*, **2021**, 18, 966-973	1.1	1
21	A Second-Generation Fungerp Analog, SCY-247, Shows Potent Activity in a Murine Model of Hematogenously Disseminated Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	1
20	Epidemiology of Onychomycosis **2018**, 13-20		1
19	A Microbiome-Driven Approach to Combating Depression During the COVID-19 Pandemic. *Frontiers in Nutrition*, **2021**, 8, 672390	6.2	1
18	Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota.. *Antibiotics*, **2022**, 11,	4.9	1
17	Diagnosing Onychomycosis: What New?. *Journal of Fungi (Basel, Switzerland)*, **2022**, 8, 464	5.6	1
16	Evaluation of Microbiome Alterations Following Consumption of BIOHM, a Novel Probiotic.. *Current Issues in Molecular Biology*, **2021**, 43, 2135-2146	2.9	0
15	Heparin-mediated antibiotic delivery from an electrochemically-aligned collagen sheet. *Bio-Medical Materials and Engineering*, **2021**, 32, 159-170	1	0
14	Characterization and functional analysis of microbiome in bladder cancer.. *Journal of Clinical Oncology*, **2022**, 40, 541-541	2.2	0
13	Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. *Antibiotics*, **2022**, 11, 722	4.9	0
12	Mycobiome Supporting Diet to Reduce Gastrointestinal (GI)Toxicity Associated with Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM). *Blood*, **2021**, 138, 3948-3948	2.2	
11	Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes. *Blood*, **2018**, 132, 5754-5754	2.2	
10	Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes. *Blood*, **2018**, 132, 4627-4627	2.2	
9	Antimicrobial Effects of Photosensitized Silicon Phthalocyanine (Pc) 4 **2016**, 521-530		
8	Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida auris Using an Immunocompromised Murine Model of Disseminated Candidiasis. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0054921	5.9	

List of Publications

7	Characterization of fungal mycobiome in bladder cancer.. *Journal of Clinical Oncology*, **2022**, 40, 542-542	2.2
6	Indole-3-acetic acid synthesized through the indole-3-pyruvate pathway promotes Candida tropicalis biofilm formation **2020**, 15, e0244246	
5	Indole-3-acetic acid synthesized through the indole-3-pyruvate pathway promotes Candida tropicalis biofilm formation **2020**, 15, e0244246	
4	Indole-3-acetic acid synthesized through the indole-3-pyruvate pathway promotes Candida tropicalis biofilm formation **2020**, 15, e0244246	
3	Indole-3-acetic acid synthesized through the indole-3-pyruvate pathway promotes Candida tropicalis biofilm formation **2020**, 15, e0244246	
2	The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). *Current Issues in Molecular Biology*, **2022**, 44, 2015-2028	2.9
1	An Immunocompromised Mouse Model of Candida auris Systemic Infection. *Methods in Molecular Biology*, **2022**, 317-328	1.4